Saturday 17 October 2026
Export SLN’s income statement to Excel — free account
Silence Therapeutics PLC Sponsored ADR
Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.
8.68
0.67
−7.17%
Follow SLN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
9.49 | 513.72 | 296.69 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(22.51) | (16.61) | (15.95) | — | |
P/B ratio |
3.31 | 4.61 | 0.00 | — | |
Price to Tangible BV |
3.88 | 5.59 | 0.00 | — | |
EV/Sales |
5.54 | 361.63 | 213.24 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(1.97) | (3.25) | (2.73) | — | |
EV/FCF |
(1.97) | (3.24) | (2.73) | — | |
Quick Ratio |
7.16 | 7.87 | 8.82 | 6.40 | |
Current Ratio |
7.69 | 8.72 | 9.83 | 7.42 | |
Net Debt/EBITDA |
3.92 | 6.89 | 4.48 | 5.24 | |
Debt/Assets |
0.00% | 0.05% | 0.04% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.14 | 0.00 | 0.01 | 0.00 | |
Operating CF/Net income |
0.52 | 1.47 | 1.04 | (0.12) | |
Capex/Depreciation |
(0.02) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
12,920.75% | 25,732.35% | 2,161.61% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
3,644.65% | 10,982.35% | 1,664.93% | 0.00% | |
Intangible Assets out of Total Assets |
0.07 | 0.08 | 0.09 | 0.10 | |
Share Based Compensation of Revenue |
1,594.34% | (252.94%) | 579.86% | 0.00% | |
Graham Net Nets |
0.25 | 0.17 | 0.15 | — | |
Graham Number |
0.00 | 0.00 | 6.12 | — | |
Earnings Yield |
(26.01%) | (30.76%) | (30.17%) | — | |
Free Cash Flow Yield |
(29.61%) | (21.70%) | (26.36%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Operating CF per Share |
(0.23) | (0.37) | (0.33) | 0.03 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.23) | (0.37) | (0.33) | 0.03 | |
Cash per Share |
2.16 | 1.80 | 1.48 | 1.53 | |
Shareholders Equity per Share |
1.57 | 1.32 | 1.05 | 0.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.57 | 1.32 | 1.05 | 0.81 | |
Free Cash Flow |
(10.89) | (17.29) | (15.60) | 1.52 | |
Working Capital |
116.25 | 105.05 | 92.39 | 81.57 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
60.91 | 49.52 | 37.13 | 26.34 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.02 | 0.00 | 0.00 | — | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
21.86 | 23.69 | 19.53 | 14.67 | |
Average Payables |
17.78 | 14.88 | 14.59 | 13.46 | |
Average Assets |
183.54 | 167.04 | 150.21 | 135.82 | |
Average Common Equity |
98.49 | 98.16 | 31.67 | 66.31 |
Columns are period end dates